Dubail Johanne, Cormier-Daire Valérie
Université de Paris, INSERM UMR 1163, Institut Imagine, Paris, France.
Service de Génétique Clinique, Centre de Référence Pour Les Maladies Osseuses Constitutionnelles, AP-HP, Hôpital Necker-Enfants Malades, Paris, France.
Front Genet. 2021 Jun 16;12:642097. doi: 10.3389/fgene.2021.642097. eCollection 2021.
Chondrodysplasias with multiple dislocations form a group of severe disorders characterized by joint laxity and multiple dislocations, severe short stature of pre- and post-natal onset, hand anomalies, and/or vertebral anomalies. The majority of chondrodysplasias with multiple dislocations have been associated with mutations in genes encoding glycosyltransferases, sulfotransferases, and transporters implicated in the synthesis or sulfation of glycosaminoglycans, long and unbranched polysaccharides composed of repeated disaccharide bond to protein core of proteoglycan. Glycosaminoglycan biosynthesis is a tightly regulated process that occurs mainly in the Golgi and that requires the coordinated action of numerous enzymes and transporters as well as an adequate Golgi environment. Any disturbances of this chain of reactions will lead to the incapacity of a cell to construct correct glycanic chains. This review focuses on genetic and glycobiological studies of chondrodysplasias with multiple dislocations associated with glycosaminoglycan biosynthesis defects and related animal models. Strong comprehension of the molecular mechanisms leading to those disorders, mostly through extensive phenotypic analyses of and/or models, is essential for the development of novel biomarkers for clinical screenings and innovative therapeutics for these diseases.
伴有多处脱位的软骨发育不全形成一组严重疾病,其特征为关节松弛和多处脱位、产前和产后发作的严重身材矮小、手部异常和/或脊柱异常。大多数伴有多处脱位的软骨发育不全与编码糖基转移酶、磺基转移酶和转运蛋白的基因突变有关,这些基因参与糖胺聚糖(由重复二糖键连接到蛋白聚糖的蛋白质核心组成的长链且无分支的多糖)的合成或硫酸化。糖胺聚糖生物合成是一个严格调控的过程,主要发生在高尔基体中,需要众多酶和转运蛋白的协同作用以及适当的高尔基体环境。这一系列反应中的任何干扰都将导致细胞无法构建正确的聚糖链。本综述聚焦于伴有与糖胺聚糖生物合成缺陷相关的多处脱位的软骨发育不全的遗传学和糖生物学研究以及相关动物模型。通过对模型进行广泛的表型分析,深入理解导致这些疾病的分子机制,对于开发用于临床筛查的新型生物标志物以及针对这些疾病的创新疗法至关重要。